These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38519766)
1. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma. Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766 [TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition. Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700 [TBL] [Abstract][Full Text] [Related]
3. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma. Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737 [TBL] [Abstract][Full Text] [Related]
4. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma. Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824 [TBL] [Abstract][Full Text] [Related]
5. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459 [TBL] [Abstract][Full Text] [Related]
6. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression. Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096 [TBL] [Abstract][Full Text] [Related]
7. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma. Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709 [TBL] [Abstract][Full Text] [Related]
8. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717 [TBL] [Abstract][Full Text] [Related]
9. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients. Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099 [TBL] [Abstract][Full Text] [Related]
10. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176 [TBL] [Abstract][Full Text] [Related]
11. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma. Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922 [TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885 [TBL] [Abstract][Full Text] [Related]
13. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365 [TBL] [Abstract][Full Text] [Related]
14. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy. Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300 [TBL] [Abstract][Full Text] [Related]
15. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357 [TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609 [TBL] [Abstract][Full Text] [Related]
17. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635 [TBL] [Abstract][Full Text] [Related]
18. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis. Bolek H; Yekedüz E; Ürün Y Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099 [TBL] [Abstract][Full Text] [Related]
19. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T Target Oncol; 2023 Jan; 18(1):159-168. PubMed ID: 36571708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]